Mycoplasma Testing Market Share, Growth, Demand and Future Revenue 2032: SPER Market Research

Q: How can I get the sample report on the Mycoplasma Testing Market?

You can get the sample pages by clicking the link - Click Here

Published: Dec 2022	Report ID: HLCA2230	Pages: 1 - 233	Formats^*:
Category : Healthcare

Global Mycoplasma Testing Market Overview:

According to SPER Market Research, the Global Mycoplasma Testing Market is estimated to reach USD 3.05 billion by 2032 with a CAGR of 13.43%.

In essence, mycoplasma testing is a type of medical test done by medical experts to help you quickly identify or exclude mycoplasma contamination of your cell cultures. This strategy entails a series of examinations that evaluate the blood antibodies created in response to a mycoplasma infection or that directly identify the organism through culture or by detecting its genetic material (DNA) in a body sample. Mycoplasma contamination is a frequent and ongoing problem in many cell culture techniques used in life science research and the pharmaceutical industry. Mycoplasmas can reach high titers in culture medium without exhibiting typical bacterial contamination indications like turbidity. They result in chromosomal defects, reduced proliferation, and altered metabolism in cultured cells. In short, Mycoplasma infection compromises both the validity of data from damaged cell lines and the results of life science research. Therefore, Mycoplasma testing is essential for cell-based research and the manufacture of goods where consumer health is a top priority. This leads to the preservation of contamination-free cell cultures.

Impact of COVID-19 on the Global Mycoplasma Testing Market

Mycoplasma testing services are in high demand because to the corona virus pandemic and the discovery of Mycoplasma pneumoniae in SARS-CoV-2 patients. This is mostly because patients with pre-existing medical illnesses have difficulties such as cytokine, autoimmune activation and hemodynamic malfunction, mitochondrial dysfunction, and other symptoms that are difficult to treat. Mycoplasma have consistently been identified as co-infections in a wide range of clinical disorders, and in some cases, this has progressed to a lethal illness, according to investigations. Medical practitioners have recently been told by published studies that COVID-19 patients may additionally harbour Mycoplasma pneumoniae or other illnesses in addition to the COVID-19. In light of this, individuals who exhibit pneumonia symptoms according to COVID-19 should undergo mycoplasma testing. Such instances are predicted to raise interest in mycoplasma testing in diagnostic and pathological settings. It is expected that in the following months, demand for mycoplasma diagnostics will rise in a number of different countries throughout the world due to the rising prevalence of coinfections in COVID-19 patients, with a high probability that they were caused by Mycoplasma pneumonia.

Get more information on this report: Download Free Sample PDF

Scope of the Report:

Report Metric	Details
Market size available for years	2019-2032
Base year considered	2021
Forecast period	2022-2032
Segments covered	By Technology, By Product & Services, By Distribution Channel, By Application, By End Use
Regions covered	North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered	Agilent Technologies, American Type Culture Collection, Asahi Kasei Medical Co. Ltd., Biological Industries Israel Beit Haemek Ltd., Bionique Testing Laboratories Inc., Biotools B & M Labs, Charles River Laboratories International Inc., Clongen Laboratories Inc., Creative Bioarray, Eurofins Scientific, GenBio,GeneCopoeia Inc., InvivoGen, Lonza Group Ltd., Merck KGaA, Meridian Bioscience Inc., Minerva Biolabs GmbH, Mycoplasma Experience, Nelson Laboratories Fairfield Inc., NorgenBiotek Corp., PromoCell GmbH, Roche Diagnostics, Sartorius AG, Savyon Diagnostics, ScienCell Research Laboratories Inc.,Thermo Fisher Scientific Inc.

Global Mycoplasma Testing Market Segmentation:

By Technology: Based on the Technology, Global Mycoplasma Testing Market issegmented as; Direct Assay, DNA Staining, ELISA, Enzymatic Methods, Indirect Assay, PCR, Others.

By Product & Services: Based on the Product& Services, Global Mycoplasma Testing Market is segmented as;Assays, Kits, & Reagents (Elimination Kits, ELISA Assays, Kits, & Reagents, Nucleic Acid, Detection Kits, PCR Assay, Stains, Standards & Controls, Others), Instruments, Services.

By Distribution Channel: Based on the Distribution Channel, Global Mycoplasma Testing Market is segmented as; Direct Tenders, Retail.

Global Mycoplasma Testing Market, By Application:
Based on the Application, Global Mycoplasma Testing Market is segmented as;Cell Line Testing, End-Of-Production Cell Testing, Virus Testing, Others.

By End Use: Based on the End Use, Global Mycoplasma Testing Market is segmented as;Academic Research Institutes, Cell Banks & Laboratories, Clinics, Community Healthcare, Contract Research Organizations, Hospitals and Surgical Centers, Oncology Centers, Pharmaceutical & Biotechnology Companies, Others.

By Region: North America owns the prime share of this market; the major factors of the market's growth in the region is this industry is anticipated to gain its market share because of its well-established healthcare industry and the rising prevalence of respiratory ailments. Additional reasons supporting the rise of this region include the presence of global pharmaceutical and biotech businesses as well as significant investments in R&D operations in the area. Due to rising healthcare expenditure and the need for better infrastructure for laboratory and clinical research, Asia Pacific is expected to see an exponential CAGR throughout the anticipated time period. Additionally, healthcare organisations' regulatory policies supporting enhancements in bio - safety quality are projected to stimulate future development prospects.

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1 Research data source

2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s

2.2 Market size estimation

2.2.1 Top-down and Bottom-up approach

2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis

4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges

4.2. COVID-19 Impacts of the Global Mycoplasma Testing Market

5. Market variables and outlook

5.1. SWOT analysis

5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats

5.2. PESTEL analysis

5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape

5.3. PORTER’S five forces analysis

5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry

5.4. Heat map analysis

6. Global Mycoplasma Testing Market, By Technology, 2019-2032 (USD Million)

6.1. Direct Assay
6.2. DNA Staining
6.3. ELISA
6.4. Enzymatic Methods
6.5. Indirect Assay
6.6. PCR
6.7. Others

7. Global Mycoplasma Testing Market, By Product& Services, 2019-2032 (USD Million)

7.1. Assays, Kits& Reagents

7.1.1. Elimination Kits
7.1.2. ELISA Assays, Kits, & Reagents
7.1.3. Nucleic Acid Detection Kits
7.1.4. PCR Assay
7.1.5. Stains
7.1.6. Standards & Controls
7.1.7. Others

7.2. Instruments
7.3. Services

8. Global Mycoplasma Testing Market, By Distribution Channel, 2019-2032 (USD Million)

8.1. Direct Tenders
8.2. Retail

9. Global Mycoplasma Testing Market,By Application, 2019-2032 (USD Million)

9.1. Cell Line Testing
9.2. End-Of-Production Cell Testing
9.3. Virus Testing
9.4. Others

10. Global Mycoplasma Testing Market, By End Use, 2019-2032 (USD Million)

10.1 Academic Research Institutes
10.2 Cell Banks & Laboratories
10.3 Clinics
10.4 Community Healthcare
10.5 Contract Research Organizations
10.6 Hospitals and Surgical Centers
10.7 Oncology Centers
10.8 Pharmaceutical & Biotechnology Companies
10.9 Others

11. Global Mycoplasma Testing Market, By Region, 2019-2032 (USD Million)

11.1 North America

11.1.1. United States
11.1.2. Canada
11.1.3. Mexico

11.2 Europe

11.2.1. Germany
11.2.2. United Kingdom
11.2.3. France
11.2.4. Italy
11.2.5. Spain

11.2.6. Rest of Europe

11.3 Asia-Pacific

11.3.1. China
11.3.2. Japan
11.3.3. India
11.3.4. Australia
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific

11.4 South America

11.4.1. Brazil
11.4.2. Argentina
11.4.3. Rest of South America

11.5 Middle East & Africa

11.5.1. Kingdom of Saudi Arabia
11.5.2. United Arab Emirates
11.5.3. Rest of Middle East & Africa

12. Company Profiles

12.1 Agilent Technologies

12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments

12.2 American Type Culture Collection

12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments

12.3 Asahi Kasei Medical Co. Ltd.

12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments

12.4 Biological Industries Israel Beit Haemek Ltd.

12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments

12.5 Bionique Testing Laboratories Inc.

12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments

12.6 Biotools B & M Labs

12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments

12.7 Charles River Laboratories International Inc.

12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments

12.8 Clongen Laboratories Inc.

12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments

12.9 Creative Bioarray

12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments

12.10 Eurofins Scientific

12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments

12.11 GenBio

12.11.1. Company details
12.11.2. Financial outlook
12.11.3. Product summary
12.11.4. Recent developments

12.12 GeneCopoeia Inc.

12.12.1. Company details
12.12.2. Financial outlook
12.12.3. Product summary
12.12.4. Recent developments

12.13 InvivoGen

12.13.1. Company details
12.13.2. Financial outlook
12.13.3. Product summary
12.13.4. Recent developments

12.14 Lonza Group Ltd.

12.14.1. Company details
12.14.2. Financial outlook
12.14.3. Product summary
12.14.4. Recent developments

12.15 Merck KGaA

12.15.1. Company details
12.15.2. Financial outlook
12.15.3. Product summary
12.15.4. Recent developments

12.16 Meridian Bioscience Inc.

12.16.1. Company details
12.16.2. Financial outlook
12.16.3. Product summary
12.16.4. Recent developments

12.17 Minerva Biolabs GmbH

12.17.1. Company details
12.17.2. Financial outlook
12.17.3. Product summary
12.17.4. Recent developments

12.18 Mycoplasma Experience

12.18.1. Company details
12.18.2. Financial outlook
12.18.3. Product summary
12.18.4. Recent developments

12.19 Nelson Laboratories Fairfield Inc.

12.19.1. Company details
12.19.2. Financial outlook
12.19.3. Product summary
12.19.4. Recent developments

12.20 NorgenBiotek Corp.

12.20.1. Company details
12.20.2. Financial outlook
12.20.3. Product summary
12.20.4. Recent developments

12.21 PromoCell GmbH

12.21.1. Company details
12.21.2. Financial outlook
12.21.3. Product summary
12.21.4. Recent developments

12.22 Roche Diagnostics

12.22.1. Company details
12.22.2. Financial outlook
12.22.3. Product summary
12.22.4. Recent developments

12.23 Sartorius AG

12.23.1. Company details
12.23.2. Financial outlook
12.23.3. Product summary
12.23.4. Recent developments

12.24 Savyon Diagnostics

12.24.1. Company details
12.24.2. Financial outlook
12.24.3. Product summary
12.24.4. Recent developments

12.25 ScienCell Research Laboratories Inc.

12.25.1. Company details
12.25.2. Financial outlook
12.25.3. Product summary
12.25.4. Recent developments

12.26 Thermo Fisher Scientific Inc.

12.26.1. Company details
12.26.2. Financial outlook
12.26.3. Product summary
12.26.4. Recent developments

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3

Frequently Asked Questions About This Report

How big is the Mycoplasma Testing Market?

The Mycoplasma Testing Market is projected to reach USD 3.05 billion by 2032, growing at a CAGR of 13.43% during the forecast period.

What is the growth rate of the Mycoplasma Testing Market?

The Mycoplasma Testing Market grew in market size from 2021. The Market is expected to reach USD 3.05 billion by 2032, at a CAGR of 13.43% during the forecast period.

What is the anticipated CAGR of the Mycoplasma Testing Market during the forecast period?

The Mycoplasma Testing Market CAGR of 13.43% during the forecast period.

How can I get the sample report on the Mycoplasma Testing Market?

You can get the sample pages by clicking the link -Click Here

What is the market size of the Mycoplasma Testing Market in 2032?

The Mycoplasma Testing Market size is USD 3.05 billion from 2022 to 2032.

Which segment is expected to lead the Mycoplasma Testing Market the forecast period?

The Mycoplasma Testing Market segment is Covered By Technology, By Product & Services, By Distribution Channel, By Application, By End Use.

Which region is expected to have the highest market share in the Mycoplasma Testing Market?

The North America and Europe region is anticipated to have the highest market share in the Mycoplasma Testing Market.

What is the conclusion of the Mycoplasma Testing Market?

Mycoplasma contamination is a frequent and ongoing problem in many cell culture techniques used in life science research and the pharmaceutical industry. Mycoplasmas can reach high titers in culture medium without exhibiting typical bacterial contamination indications like turbidity.

Who are the key players in Mycoplasma Testing Market?

The key players in the market include Companies Covered Agilent Technologies, American Type Culture Collection, Asahi Kasei Medical Co. Ltd., Biological Industries Israel Beit Haemek Ltd., Bionique Testing Laboratories Inc., Biotools B & M Labs, Charles River Laboratories International Inc., Clongen Laboratories Inc., Creative Bioarray, Eurofins Scientific, GenBio,GeneCopoeia Inc., InvivoGen, Lonza Group Ltd., Merck KGaA, Meridian Bioscience Inc., Minerva Biolabs GmbH, Mycoplasma Experience, Nelson Laboratories Fairfield Inc., NorgenBiotek Corp., PromoCell GmbH, Roche Diagnostics, Sartorius AG, Savyon Diagnostics, ScienCell Research Laboratories Inc.,Thermo Fisher Scientific Inc.